INDEX

Note: Page numbers of article titles are in boldface type.

Abortion, safe, women's health issue, 345-346
Abuse, physical, death in women due to, 343
Acquired immunodeficiency syndrome (AIDS), 1993, 276-277
1996, 277
global pandemic of, 275-285
health strategy for, 282-285
response to, 277-278
risk factors for, 281-282
societal discrimination against, 281-282
vaccines for, 278-280
vulnerability to, 280-281
Action in International Medicine (AIM) network, district hospitals and,
391-405
Acyclovir, indications, antiviral, 274
Aga Khan University, efforts to improve health care systems, 428-431
AIDS. See Acquired immunodeficiency syndrome.
AIM network. See Action in International Medicine (AIM) network.
Amantadine/rimantidine, indications, antiviral, 274
Amphotericin B, for systemic mycoses, 301-303
Antifungal agents, for systemic mycoses, 301-307
Antiviral drugs, infection resistance of, 274
Azoles, antifungal, for systemic mycoses, 303-305

Bacteriophage, virulence factor, 273
Behavior changes, human demographics and, emerging infections, 271
innovation and, 245-264
culture of biomedicine, 262-264
family as source of insight and locus of persuasion, 261-262
pitfalls, 255-257
preparation for, 250-255
accuracy, 256-257
clinical vignettes, 251
direct observation, 253
drawings/pictures/objects, 251
focus groups, 252-253
interviews, 250-251
key informants, 250-251
participant-observer study, 250
report, 257
reproducibility, 256-257
social marketing, 253-255
surveys and questionnaires, 251-252
subcultures, 258-261
neglected dimension of, 257-258
Ben-Gurion University, efforts to improve health care systems, 428-431
Biased hypermutation, 272
Biomedicine, culture of, 262-264

Center for International Health at Case Western University (CWRU), 433-437
Cervical actopy, as risk factor for HIV transmission, 289
Charles R. Drew School, efforts to improve health care systems, 427-431
Children, mortality of, in developing countries, 337
Chlamydia, death in women due to, in developing countries, 342
Ciclopirox, for systemic mycoses, 305
Circumcision, female, death in women due to, in developing countries, 342-343
Coccidioidomycosis, vaccines for, 307
Contraception, access to, women's health issue, 345-346
“Coping with Biomedical and Health Information,” 372

Developing countries, AIM network in,
391-405
Developing countries (Continued)
diarrhea in, 313–324. See also Diarrhea,
in developing countries.
information systems in, 372
mortality among children in, 337
mortality among women in, causes, 339–343
systemic mycoses in, 300–301
Diarrhea, in developing countries, 313–324
causes, 315–316, 320
control and prevention, 316–320
family planning in, 319
food and nutrient supplementation in, 318
health care programs in, 318–319
immunologic control in, 320
personal and food hygiene in, 317–318
vector control in, 319–320
water and sanitation in, 317
invasive diarrhea, 315
magnitude of the problem, 313–314
mortality from, 314
nutritional status and, 314–315
persistent diarrhea, 315
prevalence, 313–314
invasive, 315
persistent, 315
Dideoxycytidine, indications, antiviral, 274
Dideoxyinosine, indications, antiviral, 274
Diphtheria, vaccines for, history of, 327
District hospitals, and the AIM network, 391–405
functions of, 396–398
personal experience with, 399–400
secondary health care/primary health care interface, 400–401
training physicians for, 401–403
Economic development, in developing countries, emerging infections and, 271–272
Ectopy, cervical, as risk factor for HIV transmission, 289
Education, medical, for international health, 445–451
“Empty vessels, fallacy of;” 245–250
Endemic mycoses, 297
Equity, health, 224–225
Essential national health research (ENHR), 416
Ethical issues, in health for all beyond year 2000, 223–233
ethical transitions of health professionals, 229–232
going to scale, 227
humans within nature, 235–244. See also Nature, humans within.
interventions into animate life, 240–244
research, 227–228
self-reliance, 227
surveillance for equity, 224–225
Expanded Program on Immunization (EPI), 228–229
“Fallacy of the empty vessel,” 245–250
Family, as source of insight and persuasion, 261–262
Family planning, in developing countries, in prevention and control of diarrhea, 319
programs, women’s health issue, 346
Flucytosine, for systemic mycoses, 303–305
Flucytosine, for systemic mycoses, 303
Foscarnet, indications, antiviral, 274
Ganciclovir, indications, antiviral, 274
Gender discrimination, addressing of, women’s health issue, 347–348
Genetic rearrangement, 272
Genetic reassortment, 272
Global AIDS Policy Coalition, 1993, 276–277
1996, 277
Global burden of illness, 265–268
Going to scale, community-based primary health care projects and, 227
Harvard’s “library of the future,” 367
Health, international. See International health.
of women, 335–351. See also Women, health of.
Health care, primary, community-based, examples, 225–226
going to scale, 227
self-reliance, 227
programs, in prevention and control of diarrhea, 318–319
Health care systems, efforts of medical schools to improve, 425–431
types, 426
Health equity, defined, 224
surveillance for, 224–225
Health professionals, ethics of, transition in, 228–229
international, ethics of, changes in, 229–232
women’s health issue, 346–347
Hepatitis B, vaccines for, history of, 328
HIV. See Human immunodeficiency virus.
Hospital(s), district. See District hospitals.

Human immunodeficiency virus (HIV), heterosexual transmission of, risk factors for, 288-290
slowin of, 285-296
educational campaigns, 291
goals and objectives, 291
interventional research, 290
interventions, 290-294
mass media, 291
physical and chemical barriers, 293-294
testing, 294
identification of, 275-276

Hypermunatior, biased, 272

Idoxuridine, indications, antiviral, 274
IHMEC. See International Health Medical Education Consortium.

Immunization, 325-333. See also Vaccine(s).
current problems related to, 329-331
future challenges related to, 331-333
history of, 326-329

Immunomodulation, for systemic mycoses, 306

Immunosuppressed patients, as risk factor for HIV transmission, 289

Infection. See also specific types.
antiviral drugs for, 274
emerging, in tropical countries, 270-273
economic development and land use and, 271-272
human demographics and behavior and, 271
land use and, 271-272
microbial adaptation and, 272-273
population movement and, 272

Infectious diseases, in developing countries, 341-342

Infibulation, death due to, in developing countries, 343

Information dynamics, 367-375

Information statics, 367-375

Information systems, 367-375
current, in developed countries, 370-371
in developing countries, 372
future of, in developing countries, 373
history of, 369-370
materials and methods, 368-369
opportunities, 374

Innovation, and behavior change, 245-264.
See also Behavior changes, innovation and.

International health, AIDS, 275-285. See also Acquired immunodeficiency syndrome.

anthropology strategies for, 245-264
beyond year 2000, ethical issues, 223-233. See also Ethical issues, in health for all beyond year 2000.
implications, 394-396
issue on, 223-455
Center for International Health at Case Western University, 433-437
global burden of illness, 265-268
versus international health care, 223
medical education for, 445-451
evaluation, 449
partnerships in, 453-455
strategy for AIDS, 282-285
training, 439-443

International Health Medical Education Consortium (IHMEC), 419-423
agenda of (1991-1994), 422
components, 448
curricular consensus, 448
future of, 422-423
history of, 419-420
mission of, 420-421
resource sharing, 448
structure, 421-422

International health projects, selection of, 377-389
current system, 378-380
reform recommendations, 380-386
setting priorities, 387-389

Intramolecular recombination, 272

Itraconazole, for systemic mycoses, 303-305

Jonas, Hans, and imperative of responsibility, 235-244

Land use, in developing countries, emerging infections and, 271-272

Maalin, A.M., 275

Malaria, 268-270

Malnutrition, mass population migration and, 360

Marine Biological Laboratory's (MBL) "21st century library," 367

Mass population migrations, 353-366
and communicable disease control, 362-363
and health and nutrition surveillance, 363-364
and malnutrition, 360
mortality related to, 355-358
causes, 358-360
Mass population migrations (Continued)
public health interventions related to, 361-364
and rapid public health needs assessment, 360-361
Measles, diarrhea in developing countries
due to, 320
vaccines for, history of, 327
Medical schools, efforts to improve health
care systems, 425-431
Meningitis, vaccines for, history of,
327-328
Microbial emergence, 272-273
Mutation(s), 272
point, 272
Mycoses, endemic, defined, 297
locations, 297
types, 297
systemic, antifungal agents for, 301-307
amphotericin B, 301-303
azoles, 303-305
fluconazole, 303-305
itraconazole, 303-305
ketoconazole, 303-305
new drug classes, 305-306
nikkomycin, 306
papulocandins, 305-306
pneumocandins, 305-306
polymyxins, 301-303
penicilliosis, location, 297
Pertussis, vaccines for, history of, 327
Physical abuse, death in women due to,
343
Plasmid, virulence factor, 273
Plasmodium species, infection with, 268-270
Pneumocandins, for systemic mycoses,
305-306
Point mutations, 272
Polio, vaccines for, history of, 327
Polyenes, for systemic mycoses, 301-303
Population movement, emerging infections
and, 272
Pradimycin, for systemic mycoses, 306
Pregnancy, death due to, in developing
countries, 341
Primary health care, described, 391
Promiscuity, as risk factor for HIV
transmission, 288-289
Public health, interventions in mass
population migrations, 361-364
war and, 354-360
Rabies, vaccines for, history of, 326
Rapid needs assessment, mass population
migration and, 360-361
Recombinant human granulocyte
stimulation factor, for systemic
mycoses, 306
Recombination, 272
between deletion mutations, 272
intrageneric, 272
Reductionism, and philosophy of nature,
236-237
Refugees, mortality of, 355-358
causes, 358-360
Rehabilitation, nature's, 237-240
Research, health for all beyond year 2000,
227-228
Sch51048, for systemic mycoses, 305
Secondary health care, beyond year 2000, 394-398
implications for international health, 394-396
in Nigeria, 398
described, 391-392
Selective Medical Libraries on Microfiche (SMLM), 372
Self-care, women's health issue, 347
Sexually transmitted diseases (STDs),
death in women due to, in developing
countries, 341-342
as risk factor for HIV transmission, 289
Smallpox, vaccines for, history of, 328
Social marketing, 253-255
Students and Residents Advocates (SARA), of IHMEC, 421--422
Subcultures, in people's thinking and
behavior, 258-261
Surveillance for equity, 224-225
Systemic mycoses, beyond year 2000,
297–311. See also Mycoses, systemic, beyond year 2000.

Tertiary health care, described, 391
Tetanus, vaccines for, history of, 327
Training, international health, 439–443
program design, 440–442
Transposon, virulence factor, 273
Trifluridine, indications, antiviral, 274
Tropical medicine, 265–274
described, 265
emerging infections, 270–273
global burden of illness, 265–268
helminthic disease, 270
malaria, 268–270
protozoan disease, 268–270
resistance of, specific agents, 274
schistosomiasis, 270
viral evolutionary mechanisms, 272
Tuberculosis, death in women due to, in
developing countries, 341–342
vaccines for, history of, 326–327

Uncircumcized men, as risk factor for HIV
transmission, 289
University of Arizona International Health
program, 445–451

Vaccine(s). See also Immunization.
for AIDS, 278–280
for coccidioidomycosis, 307
history of, 326–329
diphtheria, 327
hepatitis B, 328
measles, 327
meningitis, 327–328
pertussis, 327
polio, 327
rabies, 326
smallpox, 328
tetanus, 327
tuberculosis, 326–327
in prevention and control of diarrhea, in
developing countries, 320
for systemic mycoses, 307
Vidarabine, indications, antiviral, 274

War, and public health, 354–360
Women, burden of disease among,
335–341
circumcision of, death due to, 342–343
health of, 335–351
disease burden of, versus men's dis-
ease burden, 335, 336
future trends, 343–345
men's participation in, 346
rationale for improving, 336–339
strategies to improve, 345–349
mortality of, causes, 339–343

Zeneca D0870, for systemic mycoses, 305
Zidovudine, indications, antiviral, 274